4,700 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Vestcor Inc

Vestcor Inc bought a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) during the 4th quarter, Holdings Channel.com reports. The fund bought 4,700 shares of the company’s stock, valued at approximately $127,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC boosted its position in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in Structure Therapeutics during the 4th quarter valued at $40,000. Assetmark Inc. boosted its position in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares in the last quarter. Jones Financial Companies Lllp boosted its position in Structure Therapeutics by 29.8% during the 4th quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock valued at $115,000 after acquiring an additional 971 shares in the last quarter. Finally, Spire Wealth Management bought a new stake in Structure Therapeutics during the 4th quarter valued at $243,000. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

GPCR has been the topic of several recent research reports. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating for the company. Finally, JMP Securities reiterated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $21.11 on Wednesday. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -28.53 and a beta of -2.37. The business has a fifty day moving average of $25.08 and a 200 day moving average of $32.09. Structure Therapeutics Inc. has a 1 year low of $19.39 and a 1 year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, equities research analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.